Lucentis

Traffic light go start restart green light

Pharma

After 3 CRLs, FDA approves Outlook's AMD drug Lytenava

The FDA has approved Outlook's Lytenava for wet age-related macular degeneration. The compound has been used off-label in the indication for two decades.

Kevin Dunleavy Jul 27, 2026 11:51am

FDA gives thumbs-up to Roche's Susvimo as treatment for DME

Feb 4, 2025 3:15pm

Italy opens antitrust case against Novartis, Biogen and others

Jun 6, 2024 11:39am

A gavel in the foreground with the scale of justice in the background

Appeals court backs Regeneron's antitrust suit against Novartis

Mar 19, 2024 10:40am

Sandoz buys Coherus' Lucentis biosimilar Cimerli for $170M

Jan 22, 2024 11:55am

Novartis targets Xiidra in eye disease asset sale: Bloomberg

Mar 14, 2023 10:22am